These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 11856618)

  • 21. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.
    Benhamou Y; Bochet M; Thibault V; Di Martino V; Caumes E; Bricaire F; Opolon P; Katlama C; Poynard T
    Hepatology; 1999 Nov; 30(5):1302-6. PubMed ID: 10534354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients.
    Lai HW; Chang CC; Chen TH; Tsai MC; Chen TY; Lin CC
    J Formos Med Assoc; 2012 Aug; 111(8):439-44. PubMed ID: 22939662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
    AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
    Liaw YF
    J Gastroenterol Hepatol; 2002 Dec; 17 Suppl 3():S333-7. PubMed ID: 12472959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN; Chauhan R; Das BC; Sarin SK
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
    Nafa S; Ahmed S; Tavan D; Pichoud C; Berby F; Stuyver L; Johnson M; Merle P; Abidi H; Trépo C; Zoulim F
    Hepatology; 2000 Nov; 32(5):1078-88. PubMed ID: 11050059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation.
    França PH; Coelho HS; Brandão CE; Segadas JA; Quintaes RF; Carrilho FJ; Ono-Nita S; Mattos AA; Tovo C; Gouvea VS; Sablon E; Vanderborght BO
    Braz J Med Biol Res; 2007 Dec; 40(12):1605-14. PubMed ID: 17713642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
    Matthews GV; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio CL
    AIDS; 2006 Apr; 20(6):863-70. PubMed ID: 16549970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.
    Cooley L; Ayres A; Bartholomeusz A; Lewin S; Crowe S; Mijch A; Locarnini S; Sasadeusz J
    AIDS; 2003 Jul; 17(11):1649-57. PubMed ID: 12853747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population.
    Alagozlu H; Ozdemir O; Koksal B; Yilmaz A; Coskun M
    Asian Pac J Cancer Prev; 2013; 14(9):5489-94. PubMed ID: 24175847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
    Akarsu M; Sengonul A; Tankurt E; Sayiner AA; Topalak O; Akpinar H; Abacioglu YH
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1783-8. PubMed ID: 17074014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A real-time PCR assay for the quantification of hepatitis B virus DNA and concurrent detection of YMDD motif mutations].
    Ağca H; Sayıner AA; Sengönül A; Simşek I; Akarsu M
    Mikrobiyol Bul; 2011 Oct; 45(4):664-76. PubMed ID: 22090297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
    Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Determination of hepatitis B virus genotype and detection of lamivudine-resistance mutations].
    Nogales MC; Serrano MC; Suárez E; Corpas R; Pérez L; Claro R; Jarana R; Romero-Gómez M; Martín-Mazuelos E
    Gastroenterol Hepatol; 2004 Nov; 27(9):515-20. PubMed ID: 15544736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
    Sheng WH; Hung CC; Chang SY; Liu CJ; Chen MY; Hsieh SM; Kao JH; Chen PJ; Chang SC
    Clin Infect Dis; 2012 Feb; 54(4):548-55. PubMed ID: 22156858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.
    Núñez M; Pérez-Olmeda M; Díaz B; Ríos P; González-Lahoz J; Soriano V
    AIDS; 2002 Nov; 16(17):2352-4. PubMed ID: 12441815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.
    Lacombe K; Gozlan J; Boelle PY; Serfaty L; Zoulim F; Valleron AJ; Girard PM
    AIDS; 2005 Jun; 19(9):907-15. PubMed ID: 15905671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.
    Wongprasit P; Manosuthi W; Kiertiburanakul S; Sungkanuparph S
    AIDS Patient Care STDS; 2010 Apr; 24(4):205-9. PubMed ID: 20377434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
    Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
    J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.
    Dunn D; Price H; Vudriko T; Kityo C; Musoro G; Hakim J; Gilks C; Kaleebu P; Pillay D; Gilson R;
    J Acquir Immune Defic Syndr; 2021 Jan; 86(1):98-103. PubMed ID: 33306565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.